Status:
APPROVED_FOR_MARKETING
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
HIV Infections
Eligibility:
All Genders
16+ years
Brief Summary
This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or int...
Eligibility Criteria
Inclusion
- HIV positive patients who have limited or no treatment options and have documented resistance
Exclusion
- Patient has previously been on MK0518 therapy
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00377065
Last Update
April 22 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.